ArticleAACE endocrinology and diabetes
Capivasertib-Induced Refractory Hyperglycemia in a Nondiabetic Patient With Metastatic Breast Cancer.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease.Case reports in endocrinology · 2026Article
- Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Selective AKT inhibitors such as capivasertib are approved to treat hormone receptor-positive, HER2-negative advanced breast cancer. Hyperglycemia is a known side effect of these agents; however, severe hyperglycemia is uncommon. We describe a patient without known history of diabetes who developed a rare presentation of refractory, severe hyperglycemia with mixed diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) following treatment with capivasertib. Case Report: A 59-year-old female with history of obesity (body mass index 39 kg/m Discussion: While hyperglycemia is a known potential side effect of capivasertib, DKA, HHS, and refractory hyperglycemia are rare. Potential risk factors for this presentation include obesity, acute renal failure, and hemodynamic instability. Conclusion: Capivasertib can induce DKA/HHS and refractory hyperglycemia in nondiabetic patients. Prompt recognition, intensive management, and drug discontinuation are critical. This is one of the first case reports to describe sustained euglycemia following severe and refractory hyperglycemia due to capivasertib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.